Steroid hormones modulate physiological processes by a number of mechanisms including regulation of gene expression. We wondered if glucocorticoids might induce expression of al adrenergic receptors, which could contribute to the increased sensitivity of vascular smooth muscle to catecholamines that may occur with glucocorticoid excess. We examined the effects of dexamethasone on the expression of the alB adrenergic receptor gene in DDT1 MF-2 smooth muscle cells. Dexamethasone (10' M) produced a 1.8±0.2-fold increase in expression of alB receptors determined with VI-Hprazosin. Steady-state values of aiB adrenergic receptor mRNA, analyzed by Northern blotting, increased 2.8±0.7-fold after 48 h exposure to dexamethasone. This effect of dexamethasone occurred in the presence of the protein synthesis inhibitor cycloheximide. alB receptor mRNA abundance was also increased by testosterone and aldosterone, whereas f estradiol and progesterone had no effect. The a1B receptor gene transcription rate, determined in nuclear run-off assays, increased 2.6±0.6-fold in cells treated with dexamethasone for 24 h. The half-life of the alB receptor mRNA was unchanged by dexamethasone. These data indicate that glucocorticoids regulate expression of aiB receptors by increasing the rate oftranscription ofthis gene. (J. Clin. Invest.
Introduction
The majority of patients withCushing's syndrome (glucocorticoid excess) have hypertension. The mechanism for hypertension in these patients is uncertain but is very likely due to several different effects ofglucocorticoids (1) . High concentrations of cortisol promote sodium retention and may activate the renin-angiotensin system. Also, glucocorticoids may decrease activity ofprostaglandin and kallikrein-kinin systems that both tend to promote vasodilitation (1) . It has been consistently observed, both in experimental animals and patients, that glucocorticoids enhance vasoconstriction mediated by catecholamines (2) (3) (4) .
Catecholamines, such as epinephrine and norepinephrine, promote vasoconstriction by activating a adrenergic receptors in vascular smooth muscle. These effects are mediated by a 1 adrenergic receptors although a2 adrenergic receptors may also contribute to vasoconstriction. Pharmacological studies have demonstrated that there are several subtypes of al receptors; the most extensively described subtypes have been termed al A and alB adrenergic receptors (5) . This demarcation between these two subtypes ofal receptors is based on differential sensitivity of a I adrenergic receptor-mediated responses to a I agonists and antagonists as well as on different requirements of a 1 adrenergic receptor-induced responses for extracellular calcium (6) . alB receptors are sensitive to the irreversible antagonist chlorethylclonidine and do not require extracellular calcium to activate smooth muscle contraction. Molecular cloning experiments have also revealed heterogeneity of a 1 adrenergic receptors; the alB receptor has been cloned from a cDNA from hamster DTTI MF2 smooth muscle cells (7, 8) .
Steroid hormones are well known to mediate physiological and developmental effects in higher eukaryotes by the regulation ofgene expression (9) . When activated by the appropriate hormone, steroid receptor proteins are thought to interact with specific target genes and modulate transcription ofthese genes. Glucocorticoids have been shown to induce transcription of f adrenergic receptor genes (10, 1 1) and indeed to increase expression of ,3 adrenergic receptors in vascular smooth muscle cells in culture (12) . We wondered if glucocorticoids might increase expression of alB adrenergic receptors in smooth muscle. Using DDT1 MF2 cells as a model system, we have found that glucocorticoids induce expression of the a lB adrenergic receptor gene. RNA preparation and Northern blotting. Total cellular RNA was isolated by the LiCI/Urea method (14) . Briefly, after rinsing with cold calcium-magnesium free phosphate buffered saline, cells were homogenized in 3 M LiCl and 6 M Urea, and incubated overnight at 4VC. RNA was pelleted by centrifugation at 12,000 g for 20 min. After extraction with phenol/chloroform, and precipitation with ethanol, poly(A)+ RNA was purified by oligo(dT) cellulose column chromatography (15) . For Northern blot analysis, poly(A)+ RNA (2 Mg) was denatured with 6% formaldehyde, fractionated by 1% agarose gel electrophoresis, and transferred to a nylon filter. The blot was prehybridized in 50% formamide, 5 X SSPE buffer, 5 x Denhardt's solution, 0.5% SDS, at 420C for 4 h, and hybridized at 420C for 12-16 h to alB adrenergic receptor cDNA (a gift from Dr. Robert J Lefkowitz and colleagues at Duke University), utilizing the 0.45-kbp BglI-BglI fragment in coding region (7) or fl-actin cDNA (16) probes that were labeled by with 32P-dCTP.
Methods
After hybridization, the filter was washed in 0.1 X SSPE, 0.1% SDS at 65°C, and exposed to Kodak XAR-5 film at -80°C with intensifying screen generally for 18-24 h. The autoradiograms were scanned using a densitometer.
Nuclear run-off transcription assay. Nuclei were prepared as de- After RNase-free DNase I and proteinase K treatments, the reaction products were extracted with phenol/chloroform and unincorporated
[32P]UTP was removed by trichloroacetic acid precipitation and filtration. The radiolabeled RNA (2-3 X I0' cpm) was dissolved in 1 ml of hybridization solution (same as above) and hybridized at 42°C for 36 h with 5 Mg of the pGEM-4Z plasmid immobilized to a nylon filter (as a control) or with immobilized plasmid-containing inserts ofa IB adrenergic receptor or (1-actin cDNA. After autoradiography, each dot was cut out and quantified by liquid scintillation counter.
Transcript stability analysis. The stability ofa IB adrenergic receptor mRNA in dexamethasone-treated and control DDT1-MF2 cells was measured by incubating the cells with 5 Mg/ml actinomycin D to block transcription (18) . After various times of incubation, total RNA was isolated from individual dishes of these actinomycin D-treated cells as described above and an RNase protection assay was performed. An RNA probe was produced by incubating a pGEM-3Z plasmid that contained a 0.35-kbp DNA fragment from the a IB adrenergic receptor cDNA with T7-RNA polymerase and [32P]UTP (100 MCi) at 37°C for 1 h. The RNA probe (5 x 101 cpm) and total RNA (25-50 M&g) were mixed and hybridized overnight at 45°C in 80% formamide, 0.4 M NaCl, 50 mM Pipes, and 1 mM EDTA. RNase buffer containing RNase A (10 Mg/ml) and RNase Tl (10 U/ml) was added to each assay tube and then incubated for 30 min at 30°C. RNase-resistant hybrids were precipitated with ethanol and run on a 5% polyacrylamide, 8 M urea gel.
Statistical analysis. Student's t test (two tailed) was used for comparing groups.
Results
To investigate the effects of glucocorticoids on a lB adrenergic Figure 1 shown).
The steady-state a IB adrenergic receptor mRNA level was measured by Northern blot analysis. Two sizes of a 1 B adrenergic receptor mRNA signal were observed in DDTI-MF2 mRNA (2.3 and 2.0 kbp), and these showed the same relative proportions throughout the experiments involving treatment with steroids (Fig. 2 A) . As both signals were positive even after washing filters at high stringency in 0.1 X SSPE at 650C, these different sizes could be due to alternative polyadenylation although this was not directly determined. We have observed an increase in the a l B adrenergic receptor mRNA as early as 2-4 h after treatment with dexamethasone, and the abundance of the mRNA progressively increased over the next hours (Fig. 2   A) . The maximal accumulation was found at 24-48 h. Throughout the experimental period there was no change in abundance of f3-actin mRNA (Fig. 2 A) . Therefore, we used fl-actin mRNA as an internal control for minor fluctuations in mRNA applied to the gel. Fig. 2 B illustrates the relative increase in alB adrenergic receptor mRNA/fl-actin mRNA ratio. The maximal increase in alB adrenergic receptor mRNA from three experiments was 2.8±0.7-fold at 48 h (n = 3, P < 0.05).
We also examined changes in alB adrenergic receptor mRNA abundance induced by other steroid hormones, including aldosterone, testosterone, fl-estradiol, and progesterone. To compare the potency and efficacy of each of these steroid hormones to induce alB adrenergic receptor mRNA abundance, the cells were incubated with varying concentrations of each steroid hormone for 24 h. As shown in Fig. 3 , dexamethasone and testosterone have the greatest and most potent capacity to induce the steady-state alB mRNA level; ECs5s were 2 X 10-10 and 3 x 10-'°M, respectively (n = 4). Aldosterone's EC5 was -100-fold less than that ofdexamethasone. These results suggest that alB adrenergic receptor mRNA is induced by both glucocorticoids and androgen receptors and possibly by mineralocorticoid receptors as well. However, the activation by aldosterone could reflect an effect mediated via a glucocorticoid receptor.
To investigate if the glucocorticoid-mediated effects required new protein synthesis, DDTI-MF2 cells were pretreated with cycloheximide (5 Ag/ml) for 2 h, and then dexamethasone was added to the medium for 24 h. As before, alB adrenergic receptor mRNA values were determined by Northern blotting. The yield of mRNA from the cycloheximide-treated cells was -50% of that from cells that had not been exposed to the protein synthesis inhibitor; in addition, the proportion of the two signals was different in the cycloheximide-treated cells. Nonetheless, dexamethasone caused the same increase in alB adrenergic receptor mRNA in cells treated with cycloheximide, as was observed in control cells treated with this glucocorticoid (Fig. 4) .
A change in abundance of the alB adrenergic receptor mRNA could result from either an alteration in the transcription rate or degradation rate ofthe mRNA. To investigate these possibilities, nuclear run-off transcription assays (to measure changes in the transcription rate ofthe alB adrenergic receptor gene) and transcript stability assays were performed. The results of these experiments were normalized to the rate of transcription of the f3-actin gene which was unchanged. The rate of transcription of the alB adrenergic receptor gene increased 2.6±0.6-fold (n = 4) in the cells that had been exposed to dexamethasone for 24 h (Fig. 5 A) . This change is similar to the increase in alB adrenergic receptor mRNA abundance measured in the Northern blotting experiments.
The stability of the alB adrenergic receptor mRNA was examined by inhibiting new mRNA transcription with actinomycin D in intact cells. After incubating the cells with dexamethasone (10-6 M) for 24 h, actinomycin D was added at a final concentration of 5 ug/ml, and the disappearance of alB adrenergic receptor mRNA with time was measured by the RNase protection assay. The yield oftotal RNA obtained from the cells was unchanged by actinomycin D for up to 8 h. These experiments demonstrated that alB receptor mRNA from cells treated with dexamethasone for 24 h had almost identical stability compared to control cells (5.1 vs. 5.3 h) (Fig. 5 B) .
Discussion
We used the DDT1-MF2 hamster smooth muscle cell line to investigate the regulation of the a l B adrenergic receptor gene by steroid hormones. DDT1 MF2 cells express a 1, #2 adrenergic receptors, and glucocorticoid and androgen receptors (19) (20) (21) (22) . In this study, we have demonstrated that a lB adrenergic receptor number and mRNA abundance in DDT1-MF2 cells is induced by glucocorticoid. This change in expression of the a I B mRNA is due to an elevated transcription rate ofthe a I B adrenergic receptor gene. Testosterone, a male sex steroid, and aldosterone, a mineralocorticoid, also induced increased abundance of the a lB adrenergic receptor mRNA. The female sex steroids estradiol and progesterone did not increase expression of this gene.
For most steroid-regulated genes, gene expression is mainly influenced by changing the transcription rate (23), but significant differences in the stability of mRNA, such as ovalbumin mRNA by estrogen (24) , have been reported. The transcription rate of a lB adrenergic receptor gene was 2.6-fold higher in the cells treated with glucocorticoid for 24 h, whereas there is almost no change in stability of the mRNA, indicating that the main change induced by dexamethasone was on gene transcription.
Steroid hormones appear to mediate their biological effects by binding to an intracellular receptor protein that is confined to target cells. Interaction ofthe hormone and its receptor leads to an alteration in the structure ofthe protein that is manifested by an increased affinity of the steroid-receptor complex to DNA (23) .
Expression of the structurally related (32 adrenergic receptor which activates adenylyl cyclase, has been found to be regulated by glucocorticoids (10, 1 1). Glucocorticoids increase the rate of transcription of this gene (10) although the pattern of change in expression for this gene is different from the a1B adrenergic receptor gene reported here. For the (3 adrenergic receptor, there is a very rapid rise in mRNA abundance (occurring within 15 min), and the maximum accumulation occurs between 1 and 2 h. The increased (2 adrenergic receptor mRNA abundance then slowly decays back to control values by 10 h in the continued presence of glucocorticoid. We could not detect an increase in mRNA level at this early time; however, while the increased expression developed more slowly, the maximum value remained increased for a much longer time (at least 48 h). These differences between the accumulation of (2 adrenergic receptor mRNA and that of the alB adrenergic receptor mRNA may be, at least in part, due to the greater stability of the latter in these cells. There was a good correlation between the increase in expression of a lB adrenergic receptor and the change in abundance of the receptor's mRNA.
Gene transcriptional regulation by steroids requires the interaction of the hormone-intracellular receptor complex with cis-regulatory sequences (25, 26) . The transcriptional induction by glucocorticoids through the glucocorticoid response element is generally rapid and does not require new protein synthesis (27) . The specificity of the elements for this steroid hormone receptor is not tightly restricted, and these elements are able to mediate induction by several hormones (28, 29). While no clear consensus sequence has yet been defined for the androgen receptor response element, a glucocorticoid response element 1 5-mer is able to mediate induction by androgens (30).
As the DNA sequence of the 5' flanking region of a lB adrenergic receptor gene has not been reported, we do not know whether glucocorticoid receptors and androgen receptors bind to the same or different DNA elements in this gene.
It is of interest to speculate that these effects of steroid hormones found in transformed smooth muscle cells could have relevance to changes in vascular smooth muscle that occur in certain forms of endocrine excess. There is extensive evidence that glucocorticoids enhance the sensitivity ofthe blood vessels to vasoconstriction induced by catecholamines (2) (3) (4) . Indeed, patients with Cushing's syndrome have been found to have increased sensitivity to norepinephrine-induced pressor responses (1) . On the other hand, it is likely that the hypertension so commonly seen in Cushing's syndrome is multifactorial, involving changes in salt balance, renin-angiotensin system, as well as effects on vasodilating mechanisms such as those mediated by prostaglandins and the kallikrein-kinin systems (1) . While some ofthe effects of excess concentrations ofglucocorticoids occur within minutes, there is evidence that glucocorticoids are important in the maintenance of a normal complement of a 1 adrenergic receptors in blood vessels from rats (31) . While testosterone has been found to increase sensitivity of blood vessels to constriction induced by catecholamines, in one study in rats, this was found to be due to a change in receptor affinity for catecholamines rather than receptor number (32) . Testosterone increases expression ofthe (32 adrenergic receptor gene in prostate (33) . The fact that the expression of the a lB receptor gene is increased by aldosterone raises the possibility that changes in these receptors in vascular smooth muscle could contribute to mineralocorticoid-induced hypertension. However, it is possible that the action ofaldosterone in DTT1 MF-2 cells may involve activation of a glucocorticoid receptor. These possibilities require direct experimental testing in animal and possibly human subjects.
We have found that the expression of the a lB adrenergic receptor gene is induced by glucocorticoids and results in an increase in the number of a lB adrenergic receptors. Even after 48 h exposure to dexamethasone, receptor number and mRNA abundance remained increased. While these changes have interest in their own right, they are raise the possibility that these types of changes could contribute to the increased sensitivity to catecholamines that is seen in certain forms of endocrine hypertension.
